Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $6.8750.

A number of equities analysts have recently commented on SRTS shares. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded up $0.13 during trading hours on Friday, hitting $3.05. 21,765 shares of the stock were exchanged, compared to its average volume of 33,346. The company’s fifty day simple moving average is $3.10 and its two-hundred day simple moving average is $3.90. The company has a market cap of $50.20 million, a PE ratio of -6.49 and a beta of 1.09. Sensus Healthcare has a 1-year low of $2.66 and a 1-year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The firm had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds have recently modified their holdings of the company. North Star Investment Management Corp. acquired a new position in Sensus Healthcare in the 1st quarter worth about $500,000. XTX Topco Ltd bought a new position in Sensus Healthcare in the 4th quarter valued at approximately $77,000. Rothschild Wealth LLC acquired a new stake in Sensus Healthcare during the 4th quarter worth approximately $500,000. Greenline Wealth Management LLC bought a new stake in Sensus Healthcare during the 4th quarter worth approximately $513,000. Finally, Ingalls & Snyder LLC bought a new stake in Sensus Healthcare during the 4th quarter worth approximately $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.